Compare CarMax, Inc (KMX) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs McKesson Corporation — how do they compare? CarMax, Inc trades at $57.84 (market cap $8.26B), while McKesson Corporation trades at $890.38 (market cap $105.14B). The key difference: McKesson Corporation is far larger — about 12.7× CarMax, Inc's market cap, and McKesson Corporation pays a 0.42% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.
| KMX | MCK | |
|---|---|---|
Market Cap | $8.26B | $105.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $62.17 | $995.69 |
52-Week Low | $30.88 | $659.01 |
Enterprise Value | $26.77B | $111.67B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $58.78, up 1.03% today, with a bullish technical signal and strong analyst support. Recent earnings have beaten expectations, with Q3 2025 and Q1 2026 EPS surpassing estimates, though Q2 2025 missed. Revenue remains stable around $26.4 billion, but net income margin is thin at 0.84%. The stock is near its consensus price target of $53.09, with a high target of $66.00. Positive news includes a Zacks Strong Buy rating and partnerships to enhance customer experience.
The outlook for KMX is cautiously optimistic, driven by earnings beats and bullish technicals, but high debt and margin pressures pose risks. Investment opportunity lies in continued execution and market share gains, while risks include competitive pressures and economic sensitivity. Analyst consensus leans Hold, with 68.58% holding, suggesting a wait-and-see approach for further growth confirmation.
McKesson (MCK) trades at $879.87, up 1.18% today, with strong momentum from recent earnings beats and raised guidance. The stock shows bullish technical signals, supported by robust revenue growth and solid cash flow generation. Recent news highlights strength in specialty drugs and oncology, driving positive sentiment.
Outlook remains favorable with a consensus price target of $990.67, though thin profit margins and high liabilities pose risks. Continued execution on growth initiatives and cost discipline are key for sustained upside, while macroeconomic pressures and competitive dynamics require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
